'On standalone basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Pfizer has increased 7.14% to Rs 603.05 crore. Operating profit margin has jumped from 31.53% to 34.83%, leading to 18.33% rise in operating profit to Rs 210.02 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 9.50% to 14.66%. Purchase of finished goods cost fell from 30.88% to 20.55%. Employee cost increased from 15.04% to 15.84%. Other expenses fell from 15.36% to 14.22%.
Other income up 60.54% to Rs 67.17 crore. PBIDT rose 26.38% to Rs 277.19 crore. Provision for interest up 54.03% to Rs 3.25 crore.
PBDT rose 26.11% to Rs 273.94 crore. Provision for depreciation down 1.30% to Rs 14.41 crore.
Profit before tax grew 28.09% to Rs 259.53 crore.&nbs...
Pleaselogin & subscribe to view the full report.
More Reports
|
|